ATE502048T1 - Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs - Google Patents
Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebsInfo
- Publication number
- ATE502048T1 ATE502048T1 AT06739100T AT06739100T ATE502048T1 AT E502048 T1 ATE502048 T1 AT E502048T1 AT 06739100 T AT06739100 T AT 06739100T AT 06739100 T AT06739100 T AT 06739100T AT E502048 T1 ATE502048 T1 AT E502048T1
- Authority
- AT
- Austria
- Prior art keywords
- chlorotoxin conjugate
- intraoperative
- visibility
- cancer
- fluorescent
- Prior art date
Links
- 101710164760 Chlorotoxin Proteins 0.000 title abstract 4
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 title abstract 4
- 229960005534 chlorotoxin Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000799 fluorescence microscopy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012800 visualization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Medical Informatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67428005P | 2005-04-22 | 2005-04-22 | |
| PCT/US2006/010170 WO2006115633A2 (en) | 2005-04-22 | 2006-03-20 | Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE502048T1 true ATE502048T1 (de) | 2011-04-15 |
Family
ID=36609637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06739100T ATE502048T1 (de) | 2005-04-22 | 2006-03-20 | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20070154965A1 (de) |
| EP (1) | EP1877428B1 (de) |
| AT (1) | ATE502048T1 (de) |
| DE (1) | DE602006020710D1 (de) |
| ES (1) | ES2360519T3 (de) |
| WO (1) | WO2006115633A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| EP1877428B1 (de) | 2005-04-22 | 2011-03-16 | University of Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| US9283288B2 (en) | 2006-02-24 | 2016-03-15 | Medibeacon, Inc. | Methods of using optical agents |
| US20090098574A1 (en) * | 2006-04-25 | 2009-04-16 | Centre National De La Recherche Scientifique (Cnrs) | Functionalization of gold nanoparticles with oriented proteins, application to the high-density labelling of cell membranes |
| US8529874B2 (en) * | 2007-05-16 | 2013-09-10 | Ge Healthcare As | Peptide imaging agents |
| CA2943712C (en) * | 2007-07-30 | 2019-06-04 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Northern Arizona University | Methods and devices for the detection of biofilm |
| JP2010535811A (ja) * | 2007-08-07 | 2010-11-25 | トランスモレキュラー， インコーポレイテッド | 薬物キャリアとしてのクロロトキシン |
| EP2211913A4 (de) * | 2007-10-12 | 2010-12-22 | Transmolecular Inc | Systemische verabreichung von chlorotoxin-mitteln zur diagnose und behandlung von tumoren |
| US7892760B2 (en) * | 2007-11-19 | 2011-02-22 | Celera Corporation | Lung cancer markers, and uses thereof |
| WO2009126835A2 (en) * | 2008-04-09 | 2009-10-15 | University Of Washington Techtransfer Invention Licensing | Magnetic nanoparticle and method for imaging t cells |
| JP5497006B2 (ja) * | 2008-04-14 | 2014-05-21 | ザ ジェネラル ホスピタル コーポレイション | 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 |
| CA2724384A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| US8697375B2 (en) * | 2008-09-02 | 2014-04-15 | University Of Maryland, Baltimore | In vivo biofilm infection diagnosis and treatment |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| WO2011142858A2 (en) * | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| WO2013003507A1 (en) * | 2011-06-27 | 2013-01-03 | Morphotek, Inc. | Multifunctional agents |
| US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
| CA2913127A1 (en) | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
| US9784730B2 (en) | 2013-03-21 | 2017-10-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| BR112016005802A2 (pt) * | 2013-09-17 | 2017-09-12 | Blaze Bioscience Inc | conjugados de clorotoxina e métodos de seu uso |
| WO2017180789A2 (en) | 2016-04-12 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treatment using chlorotoxin conjugates |
| US20190282661A1 (en) | 2016-04-15 | 2019-09-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3407582A1 (de) | 1984-03-01 | 1985-09-05 | Dornier System Gmbh, 7990 Friedrichshafen | Schaltungsanordnung fuer einen regelkreis |
| US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| US6667156B2 (en) | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
| US6130101A (en) * | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| CA2384429A1 (en) * | 1999-09-14 | 2001-03-22 | Michael K. Bahr | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| WO2001037721A2 (en) * | 1999-11-22 | 2001-05-31 | The Research Foundation Of State University Of New York | Magnetic nanoparticles for selective therapy |
| DE10020376A1 (de) * | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamische Marker |
| WO2003000203A2 (en) | 2001-06-26 | 2003-01-03 | Uab Research Foundation | Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
| US6972326B2 (en) * | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
| US20060088899A1 (en) | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| MXPA04011871A (es) | 2002-05-31 | 2005-07-26 | Transmolecular Inc | Quimioterapia en combinacion con clorotoxina. |
| US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| US20040101822A1 (en) * | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| DE10328251A1 (de) | 2003-06-24 | 2005-01-13 | Toximed Gmbh | Pharmazeutischer Wirkstoff |
| WO2005053611A2 (en) | 2003-11-26 | 2005-06-16 | Transmolecular, Inc. | Treatment of phosphatidylinositol phospholipid disorders |
| JP2007532879A (ja) | 2004-04-06 | 2007-11-15 | トランスモレキュラー， インコーポレイテッド | 骨髄およびリンパ系細胞癌の診断および処置 |
| US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
| GB0422901D0 (en) | 2004-10-14 | 2004-11-17 | Ares Trading Sa | Lipocalin protein |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| US7462446B2 (en) * | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| EP1877428B1 (de) | 2005-04-22 | 2011-03-16 | University of Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| CN102703446B (zh) | 2005-08-18 | 2014-05-28 | Ambrx公司 | tRNA组合物和其用途 |
| US20070237714A1 (en) | 2006-03-31 | 2007-10-11 | Alvarez Vernon L | Diagnosis and treatment of tumors |
| EP2029157A4 (de) | 2006-05-19 | 2009-11-18 | Georgia Tech Res Inst | Abc-transporterligand |
| CN101003788A (zh) | 2006-09-21 | 2007-07-25 | 武汉大学 | 一种蝎抗肿瘤转移肽及其制备方法和应用 |
| CN100564517C (zh) | 2006-09-21 | 2009-12-02 | 武汉大学 | 一种蝎抗神经胶质瘤肽及其制备方法和应用 |
| CA2667678A1 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| US20090004105A1 (en) | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
| JP2010535811A (ja) | 2007-08-07 | 2010-11-25 | トランスモレキュラー， インコーポレイテッド | 薬物キャリアとしてのクロロトキシン |
| EP2211913A4 (de) | 2007-10-12 | 2010-12-22 | Transmolecular Inc | Systemische verabreichung von chlorotoxin-mitteln zur diagnose und behandlung von tumoren |
| AU2008352925A1 (en) | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
| CN101270158B (zh) | 2008-04-30 | 2010-12-22 | 武汉大学 | 一种靶向抗神经胶质瘤蛋白及制备方法和用途 |
| CA2724384A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| EP2313430B1 (de) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteine von hngal und verwandter proteine mit affinität für ein vorgegebenes zielmolekül |
| US20100098637A1 (en) | 2008-09-23 | 2010-04-22 | The Regents Of The University Of Michigan | Dye-loaded nanoparticle |
| CN101381405B (zh) | 2008-09-24 | 2011-07-27 | 武汉摩尔生物科技有限公司 | 基因工程肿瘤靶向kct-w1多肽及制备方法和用途 |
| EP3483610A1 (de) | 2009-11-09 | 2019-05-15 | University Of Washington Center For Commercialization | Funktionalisierte chromophore polymerpunkte und biokonjugate daraus |
| CN101921769B (zh) | 2010-01-11 | 2012-07-25 | 山西大学 | 一种重组腺病毒及其制备方法和应用 |
| WO2011094671A2 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | N-terminally conjugated polypeptides for targeted therapy and diagnosis |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| CN101824084A (zh) | 2010-04-08 | 2010-09-08 | 山西大学 | 靶向性抗胶质瘤蛋白质及其应用 |
| WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| CN107082803A (zh) | 2010-08-16 | 2017-08-22 | 皮里斯制药有限公司 | 铁调素的结合蛋白 |
-
2006
- 2006-03-20 EP EP06739100A patent/EP1877428B1/de active Active
- 2006-03-20 WO PCT/US2006/010170 patent/WO2006115633A2/en active Application Filing
- 2006-03-20 DE DE602006020710T patent/DE602006020710D1/de active Active
- 2006-03-20 AT AT06739100T patent/ATE502048T1/de active
- 2006-03-20 ES ES06739100T patent/ES2360519T3/es active Active
- 2006-11-14 US US11/600,004 patent/US20070154965A1/en not_active Abandoned
-
2007
- 2007-08-31 US US11/897,721 patent/US8778310B2/en active Active
-
2014
- 2014-05-08 US US14/273,374 patent/US20140241993A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080279780A1 (en) | 2008-11-13 |
| EP1877428A2 (de) | 2008-01-16 |
| US8778310B2 (en) | 2014-07-15 |
| ES2360519T3 (es) | 2011-06-06 |
| EP1877428B1 (de) | 2011-03-16 |
| WO2006115633A3 (en) | 2006-12-28 |
| WO2006115633A2 (en) | 2006-11-02 |
| US20070154965A1 (en) | 2007-07-05 |
| DE602006020710D1 (de) | 2011-04-28 |
| US20140241993A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE502048T1 (de) | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs | |
| WO2007081740A3 (en) | Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers | |
| WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
| CY1114441T1 (el) | Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα | |
| TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
| WO2008046911A3 (en) | Novel human micrornas associated with cancer | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| WO2007009755A3 (en) | Compositions and methods for cancer diagnostics comprising pan-cancer markers | |
| ATE492651T1 (de) | Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| WO2007028163A8 (en) | Biocompatible fluorescent imaging agents | |
| ECSP11011338A (es) | Anticuerpos biespecíficos anti-her | |
| EP3005941A3 (de) | Intraoperative fluoreszenz-spektroskopie und anwendungen davon | |
| ZA200803672B (en) | Compositions and methods for treating tumors presenting survivin antigens | |
| WO2007081720A3 (en) | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
| WO2006015079A3 (en) | Erm family binding agents and their use in diagnosis and treatment of proliferative conditions | |
| WO2007123880A3 (en) | Methods and kits for early stage caries detection | |
| WO2010008519A3 (en) | In vitro diagnostic markers comprising carbon nanoparticles and kits | |
| WO2008045406A3 (en) | COMPOUNDS, SCREENINGS, AND METHODS OF TREATMENT | |
| DE602006013151D1 (de) | Verfahren zur herstellung von polymermaleimiden | |
| WO2008118626A3 (en) | Inhibitors of jnk and methods for identifying inhibitors of jnk | |
| WO2007056049A3 (en) | Molecular profiling of cancer | |
| DE602006014106D1 (de) | Verfahren zur diagnose von prostatakrebs | |
| WO2008031038A3 (en) | Pre- and intra-operative localization of penile sentinel nodes | |
| EP1764419A3 (de) | Verfahren zur Diagnose proliferativer Erkrankungen durch Detektion von Genmethylierung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1877428 Country of ref document: EP |